Physician profile
David Sackel
NPI 1235459512
$81,766.40
in general payments reported to CMS, 2019-2025
33 companies · $8,460 in 2025
The $8,460 reported for 2025 was more than what 95% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,759 · 2020: $2,859 · 2021: $4,697 · 2022: $6,592 · 2023: $38K · 2024: $15K · 2025: $8,460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $46K · Food and Beverage: $11K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,800 · Travel and Lodging: $1,657 · Honoraria: $1,239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $46,087.00 |
| Food and Beverage | $11,076.25 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,800.00 |
| Travel and Lodging | $1,657.32 |
| Honoraria | $1,238.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $53,491.37 | 2019-2025 | Catalys System, Tecnis Iol, Tecnis Iol |
| Alcon Vision LLC | $8,852.70 | 2019-2025 | Clareon, Lensx, Clareon Panoptix Pro |
| Glaukos Corporation | $4,101.47 | 2019-2025 | Ce-Marked Kxla System, Kxl System (Not Refurbished), Photrexa Viscous and Photrexa |
| Harrow Eye, LLC | $2,272.88 | 2024-2025 | Vevye |
| Sight Sciences, INC. | $2,142.58 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument, Tearcare System |
| Biotissue Holdings INC. | $1,913.72 | 2019-2025 | |
| Carl Zeiss Meditec USA, INC. | $1,340.96 | 2022-2025 | Veracity Surgical, Lumera 700 |
| Lensar, INC. | $1,300.00 | 2025 | Lensar Laser System |
| Sun Pharmaceutical Industries INC. | $1,261.07 | 2019-2025 | Cequa |
| Carl Zeiss Meditec, INC. | $515.32 | 2019-2020 | |
| Coopervision INC. | $514.09 | 2020-2022 | |
| Rxsight INC | $508.22 | 2023-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Bausch & Lomb Americas INC. | $428.03 | 2022-2025 | Miebo, Xiidra, Ic-8 Apthera Iol |
| Abbvie INC. | $390.55 | 2022-2025 | Durysta |
| Eyevance Pharmaceuticals LLC | $350.89 | 2020-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $334.69 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $330.03 | 2019-2021 | |
| Eyepoint US, INC. | $270.06 | 2019-2020 | |
| Tarsus Pharmaceuticals, INC. | $232.84 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $217.54 | 2022-2025 | Tyrvaya |
| Shire North American Group INC | $189.77 | 2019 | |
| Novartis Pharmaceuticals Corporation | $178.30 | 2019-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $157.53 | 2019-2021 | |
| Amgen INC. | $85.43 | 2024-2025 | Tepezza |
| Dompe US, INC. | $82.92 | 2024-2025 | Oxervate |
| Horizon Therapeutics Plc | $69.01 | 2023 | Tepezza |
| Akorn Operating Company LLC | $66.25 | 2021 | |
| Thea Pharma INC. | $44.79 | 2022-2023 | |
| Recordati_rare_diseases_inc. | $42.66 | 2022-2023 | Cystadrops |
| Leadiant Biosciences, INC. | $21.28 | 2025 | Cystaran |
| Eusa Pharma (US) LLC | $20.18 | 2022 | |
| Ocular Therapeutix, INC. | $19.87 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Sackel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.